Research on Triple Antiviral Drug Combination for COVID-19 Treatment

Background of the COVID-19 Pandemic

The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has impacted over 230 countries, resulting in more than three million confirmed cases and 200,000 deaths as estimated by the World Health Organization in early May 2020. A significant portion of the global population remains susceptible to this novel virus, which exhibits a high mortality rate, particularly among the elderly and individuals with underlying health conditions. The pandemic has not only strained healthcare systems worldwide but has also led to substantial economic repercussions.

Search for Effective Antiviral Treatments

In addition to ongoing vaccine development, researchers are actively pursuing effective antiviral treatments for patients with COVID-19. While creating new drugs specifically targeting SARS-CoV-2 may take years, existing antiviral medications for other viral infections are being repurposed. This strategy offers a quicker pathway to identifying antiviral therapies that are both effective and safe for treating COVID-19.

Hong Kong Study on Antiviral Drug Combinations

Researchers in Hong Kong conducted a study comparing a triple antiviral drug combination to a single antiviral therapy for treating mild to moderate COVID-19 illness. Their findings were published in The Lancet. The study suggests that repurposing existing antiviral drugs may yield effective treatment options for COVID-19 patients.

Rationale for Combination Therapy

Previous experience with influenza indicates that treating hospitalized patients with a combination of antiviral drugs is more effective than using a single therapy, as it reduces the risk of drug resistance. Both influenza and COVID-19 exhibit high viral loads around the onset of symptoms, prompting researchers to explore the efficacy of combining multiple antiviral drugs for treating COVID-19.

Study Design and Results

In an open, prospective, randomized, controlled trial, the researchers enrolled 127 COVID-19 patients from six public hospitals in Hong Kong. Patients received standard care and were randomly assigned, in a 2 to 1 ratio, to either a 14-day course of a triple combination antiviral therapy (interferon beta-1b, lopinavir-ritonavir, and ribavirin) or lopinavir-ritonavir alone. The researchers monitored the time taken for patients to test negative for SARS-CoV-2, along with COVID-19 symptoms, hospital stay duration, and any adverse effects.

The results indicated that the triple antiviral combination group experienced a shorter duration of viral shedding (average of 7 days) compared to the single therapy group (average of 12 days). Additionally, symptoms and length of hospital stay were also reduced in the triple therapy group without a difference in adverse effects between the two groups.

Conclusion on Efficacy and Safety

The researchers concluded that early treatment with the triple combination of antiviral drugs effectively suppressed viral load and relieved symptoms in patients with mild to moderate COVID-19, demonstrating superiority over single antiviral therapy. The treatment was found to be safe and well-tolerated, potentially reducing the risk of infection among healthcare workers by decreasing both the duration and amount of viral shedding from patients.

Future Research Directions

Despite these promising findings, the research team emphasized the need for further studies to validate their results. Additional analysis indicated that interferon beta-1b might be a crucial component of the combination therapy. Dr. Jenny Lo from Ruttonjee Hospital noted, “Interferons are naturally occurring proteins produced in response to viral infection, and we hope that interferon beta-1b will enhance the body’s ability to combat SARS-CoV-2.” Professor Kwok-Yung Yuen from the University of Hong Kong, who led the research, stated, “While these findings are encouraging, larger trials are necessary to confirm the effectiveness of interferon beta-1b alone or in combination with other drugs in patients with more severe illness, where the virus has had more time to replicate.”

References

1. Hung IFN, Lung KC, Tso EYK, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Published online. Lancet May 8, 2020 doi:10.1016/S0140-6736(20)31042-4.
2. The Lancet. Press release, 8 May 2020. “The Lancet: New triple antiviral drug combination shows early promise for treating COVID-19 in phase 2 randomized trial.” https://www.eurekalert.org/pub_releases/2020-05/tl-pss050820.php